



SEQUENCE LISTING

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

<110> PHOGEN, LIMITED
O'Hare, Peter Francis Joseph
Normand, Nadia Michelle

<120> DELIVERY OF SUBSTANCES TO CELLS

<130> 5759-54451

<140> US 09/522,278

<141> 2000-03-09

<150> GB 9930499.0

<151> 1999-12-24

<150> GB 9905444.7

<151> 1999-03-10

<160> 12

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 1

ccccaccac ttccctctc

20

<210> 2

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 2

tctctgcct tgctcaccat ggtggcgacc ggtggatccc

40

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 3

cccttgctca ccatggtggc

20

<210> 4

<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 4
accatggtgg cgaccggtgg atccc

25

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 5
cccttgctca ccatggtggc

20

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 6
ccccaccac ttccctctc

20

<210> 7
<211> 131
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 7
gatcctatgg ggcaggtggg acggcagctc gccatcatcg gggacgacat caaccgacgc 60
tatcgggatc ccgatagcgt cggttgatgt cgtccccgat gatggcgagc tgccgtccca 120
cctgccccat g 131

<210> 8
<211> 36
<212> RNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 8

guuuuuccug augaggccga aaggccgaaa uucucc

36

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 9
ccccaccac ttcccctctc

20

<210> 10
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 10
ccacaccgac ggcgccc

17

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 11
tccccgcctgt gacatgcatt

20

<210> 12
<211> 301
<212> PRT
<213> herpes simplex virus 1

<400> 12

Met Thr Ser Arg Arg Ser Val Lys Ser Gly Pro Arg Glu Val Pro Arg
1 5 10 15

Asp Glu Tyr Glu Asp Leu Tyr Tyr Thr Pro Ser Ser Gly Met Ala Ser
20 25 30

Pro Asp Ser Pro Pro Asp Thr Ser Arg Arg Gly Ala Leu Gln Thr Arg
35 40 45

Ser Arg Gln Arg Gly Glu Val Arg Phe Val Gln Tyr Asp Glu Ser Asp
50 55 60

Tyr Ala Leu Tyr Gly Gly Ser Ser Ser Glu Asp Asp Glu His Pro Glu
65 70 75 80

Val Pro Arg Thr Arg Arg Pro Val Ser Gly Ala Val Leu Ser Gly Pro
85 90 95

Gly Pro Ala Arg Ala Pro Pro Pro Pro Ala Gly Ser Gly Gly Ala Gly
100 105 110

Arg Thr Pro Thr Thr Ala Pro Arg Ala Pro Arg Thr Gln Arg Val Ala
115 120 125

Thr Lys Ala Pro Ala Ala Pro Ala Ala Glu Thr Thr Arg Gly Arg Lys
130 135 140

Ser Ala Gln Pro Glu Ser Ala Ala Leu Pro Asp Ala Pro Ala Ser Thr
145 150 155 160

Ala Pro Thr Arg Ser Lys Thr Pro Ala Gln Gly Leu Ala Arg Lys Leu
165 170 175

His Phe Ser Thr Ala Pro Pro Asn Pro Asp Ala Pro Trp Thr Pro Arg
180 185 190

Val Ala Gly Phe Asn Lys Arg Val Phe Cys Ala Ala Val Gly Arg Leu
195 200 205

Ala Ala Met His Ala Arg Met Ala Ala Val Gln Leu Trp Asp Met Ser
210 215 220

Arg Pro Arg Thr Asp Glu Asp Leu Asn Glu Leu Leu Gly Ile Thr Thr
225 230 235 240

Ile Arg Val Thr Val Cys Glu Gly Lys Asn Leu Leu Gln Arg Ala Asn
245 250 255

Glu Leu Val Asn Pro Asp Val Val Gln Asp Val Asp Ala Ala Thr Ala
260 265 270

Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr Glu Arg Pro Arg Ala
275 280 285

Pro Ala Arg Ser Ala Ser Arg Pro Arg Arg Pro Val Glu
290 295 300

#10/D

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

SEQUENCE LISTING



<110> PHOGEN, LIMITED
O'Hare, Peter Francis Joseph
Normand, Nadia Michelle

<120> DELIVERY OF SUBSTANCES TO CELLS

<130> 5759-54451

<140> US 09/522,278

<141> 2000-03-09

<150> GB 9930499.0

<151> 1999-12-24

<150> GB 9905444.7

<151> 1999-03-10

<160> 12

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 1

ccccaccac ttccctctc

20

<210> 2

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 2

tcctcgccct tgctcaccat ggtggcgacc ggtggatccc

40

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 3

cccttgctca ccatgggtggc

20

26
1

<210> 4
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Oligonucleotide primer

 <400> 4
 accatggtgg cgaccggtgg atccc 25

 <210> 5
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Oligonucleotide primer

 <400> 5
 cccttgctca ccatggtggc 20

 <210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Oligonucleotide primer

 <400> 6
 cccccaccac ttcccctctc 20

 <210> 7
 <211> 131
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Oligonucleotide primer

 <400> 7
 gatcctatgg ggcaggtggg acggcagctc gccatcatcg gggacgacat caaccgacgc 60
 tatcgggatc ccgatagcgt cggttgatgt cgtccccgat gatggcgagc tgccgtccca 120
 cctgccccat g 131

 <210> 8
 <211> 36
 <212> RNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 8

guuuuccug augaggccga aaggccgaaa uucucc

36

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 9

ccccaccac ttcccctctc

20

<210> 10

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 10

ccacaccgac ggcgccc

17

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 11

tcccgctgt gacatgcatt

20

<210> 12

<211> 301

<212> PRT

<213> herpes simplex virus 1

<400> 12

Met Thr Ser Arg Arg Ser Val Lys Ser Gly Pro Arg Glu Val Pro Arg
1 5 10 15

Asp Glu Tyr Glu Asp Leu Tyr Tyr Thr Pro Ser Ser Gly Met Ala Ser

28

20

25

30

Pro Asp Ser Pro Pro Asp Thr Ser Arg Arg Gly Ala Leu Gln Thr Arg
35 40 45

Ser Arg Gln Arg Gly Glu Val Arg Phe Val Gln Tyr Asp Glu Ser Asp
50 55 60

Tyr Ala Leu Tyr Gly Gly Ser Ser Ser Glu Asp Asp Glu His Pro Glu
65 70 75 80

Val Pro Arg Thr Arg Arg Pro Val Ser Gly Ala Val Leu Ser Gly Pro
85 90 95

Gly Pro Ala Arg Ala Pro Pro Pro Pro Ala Gly Ser Gly Gly Ala Gly
100 105 110

Arg Thr Pro Thr Thr Ala Pro Arg Ala Pro Arg Thr Gln Arg Val Ala
115 120 125

Thr Lys Ala Pro Ala Ala Pro Ala Ala Glu Thr Thr Arg Gly Arg Lys
130 135 140

Ser Ala Gln Pro Glu Ser Ala Ala Leu Pro Asp Ala Pro Ala Ser Thr
145 150 155 160

Ala Pro Thr Arg Ser Lys Thr Pro Ala Gln Gly Leu Ala Arg Lys Leu
165 170 175

His Phe Ser Thr Ala Pro Pro Asn Pro Asp Ala Pro Trp Thr Pro Arg
180 185 190

Val Ala Gly Phe Asn Lys Arg Val Phe Cys Ala Ala Val Gly Arg Leu
195 200 205

Ala Ala Met His Ala Arg Met Ala Ala Val Gln Leu Trp Asp Met Ser
210 215 220

Arg Pro Arg Thr Asp Glu Asp Leu Asn Glu Leu Leu Gly Ile Thr Thr
225 230 235 240

Ile Arg Val Thr Val Cys Glu Gly Lys Asn Leu Leu Gln Arg Ala Asn
245 250 255

Glu Leu Val Asn Pro Asp Val Val Gln Asp Val Asp Ala Ala Thr Ala
260 265 270

Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr Glu Arg Pro Arg Ala
275 280 285

Pro Ala Arg Ser Ala Ser Arg Pro Arg Arg Pro Val Glu
290 295 300